Oncology

Immunotherapy, targeted agents and the trials reshaping cancer care.

Five-year data suggest durable responses for a third of patients, but toxicity remains the trade-off.

Clara Whitfield · 1 November 2026

The Briefing

Trial results that matter, every Friday.

One email. The week's readouts, approvals and research, explained without hype.